Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B.

Blood. 1995 Jul 15;86(2):685-91.

2.

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.

Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B.

Blood. 1995 Oct 15;86(8):3123-31.

3.

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, et al.

Blood. 1991 Sep 1;78(5):1198-204.

4.

Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R.

Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201. Review.

PMID:
2104241
5.

Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.

Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J.

Clin Exp Immunol. 1994 Nov;98(2):323-9.

6.

Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B.

Blood. 1995 May 1;85(9):2521-7.

7.

Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.

Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, Goto T, Matsumoto T.

Blood. 1999 Jun 1;93(11):3922-30.

8.

Immunomodulating IL-6 activity by murine monoclonal antibodies.

Brochier J, Legouffe E, Liautard J, Gaillard JP, Mao LQ, Bataille R, Rossi JF, Klein B.

Int J Immunopharmacol. 1995 Jan;17(1):41-8.

PMID:
7782152
9.

Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.

Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH.

Leuk Lymphoma. 1998 Nov;31(5-6):551-8.

PMID:
9922045
10.

Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.

Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T.

Blood. 1995 Feb 1;85(3):757-64.

11.

Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.

Taetle R, Dos Santos B, Ohsugi Y, Koishihara Y, Yamada Y, Messner H, Dalton W.

J Natl Cancer Inst. 1994 Mar 16;86(6):450-5.

PMID:
8120920
12.

Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.

Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Koishihara Y, et al.

Jpn J Cancer Res. 1994 Sep;85(9):958-65.

PMID:
7961126
13.

Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.

Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M.

Blood. 1994 Oct 15;84(8):2472-9.

14.

CD40 ligand triggered interleukin-6 secretion in multiple myeloma.

Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC.

Blood. 1995 Apr 1;85(7):1903-12.

15.

Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.

Zhang XG, Bataille R, Widjenes J, Klein B.

Cancer. 1992 Mar 15;69(6):1373-6.

16.
17.

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC.

Blood. 1993 Dec 15;82(12):3712-20.

18.

The biologic window for chimeric L6 radioimmunotherapy.

DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, Lamborn KR, Hellstrom I, Hellstrom KE, DeNardo GL.

Cancer. 1994 Feb 1;73(3 Suppl):1023-32.

19.
20.

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, van Oers MH.

Br J Haematol. 1998 Aug;102(3):783-90.

PMID:
9722307

Supplemental Content

Support Center